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Commentary
Dr. Kundart: Hello, I am here with Dr. Abimbola 
Farinde, and we are talking today about the appropriate 
prescribing of medications for older adults, and some 
interactions that inappropriate drug prescribing may 
cause in these patients.
I wanted to ask first about Beers Criteria, also called 
the Beers List. It talks about potentially inappropriate 
medication use in older adults. I was wondering if you 
can elaborate on that for those of us who are not fa-
miliar with the Beers Criteria (http://en.wikipedia.org/
wiki/Beers_Criteria). 
Dr. Farinde: The Beers Criteria or the Beers List was 
initially developed in 1997 and was basically trying 
to help prescribers know what medication classes or 
medications in general can be viewed as appropriate or 
inappropriate in the geriatric population. Given the fact 
that as we age, we can experience some decline in organ 
functioning or even suppression of our immune system, 
these factors have to be taken into consideration when 
it comes to the use of certain medications, especially 
when it comes to renal or hepatic functioning. So the 
development of this guideline came from a consensus 
panel that consisted of individuals in pharmacotherapy 
and geriatrics, and they were able to narrow (the list) 
down to 53 key medication classes or medications. 
In general, they categorize into 3 separate categories: 
whether a medication may be inappropriate or 
contraindicated in the geriatric population; medications 
that should be used with caution in the geriatric 
population; inappropriate medications to avoid in 
older adults with specific diseases or syndromes. It is 
a guideline that most prescribers use to gauge whether 
a medication is deemed to be appropriate in a geriatric 
individual. 
Dr. Kundart: [The following question refers to U.S. Food 
and Drug Administration-established Pharmaceutical 
Pregnancy Categories] Is this similar to the way that 
medications are categorized  in pregnancy? Many of 
them are class C and have not been studied (see http://
en.wikipedia.org/wiki/Pregnancy_category)
Dr. Farinde: Correct.  There may be with some 
(similarities to) these medications. They are not included 
in many clinical trials to begin with anyway. There are 
hard, firm guidelines for which medications should not 
be used, and there guidelines for other medications 
that can be used, but (we) have to be cautious when it 
comes to their use in this sensitive population. So they 
are along the same lines as the pregnancy categories. 
Dr. Kundart: So it sounds like you are triaging the drugs 
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in a way. Some that are safe, or generally recognized 
as safe, other have safety issues, and others may be 
unknown. Would that be fair to say? Their safety can 
be based on changes in adults’ hepatic function, kidney 
function, or immune system?
Dr. Farinde: In particular, there are certain drugs that 
are well-known in terms of avoidance in the geriatric 
population. There are other drugs where there is a 
divide in terms of whether they should or should not be 
used in the geriatric population. So ultimately when it 
comes to those drug classes, it might be based on clinical 
judgment, in other words, based on what a provider has 
observed in the past in terms of what has worked with 
their patient. Even though the literature may say one 
thing, from their personal experience, some doctors see 
that the medication works for a patient, even though 
there is a recommendation against it. 
Dr. Kundart: Clinical experience is always something 
we have to steel ourselves about because it is always so 
compelling. The “n” sizes for the number of patients 
that we have seen is not significant compared to what 
we see in the literature. 
Dr. Farinde: There sometimes might be that gap between 
what research is saying versus what practitioners are 
able to apply in their clinical practice setting. I think it 
is more so being able to translate what is found in the 
literature into what people do in actual clinical practice. 
That gap can become a bit narrower. 
Dr. Kundart: Do you have a specific example or two 
about drugs that might be contraindicated in the senior 
population, because although they may be effective in 
other groups, but because of kidney function or liver 
function they may not be something you want to use 
in seniors?
Dr. Farinde: Well, there are certain drugs based on 
renal or hepatic function as well as other drug classes 
that are well-known, because of their side effect profile. 
One class in particular that kind of stands out when 
it comes to avoidance in the geriatric population 
are the anticholingergics, for example, the tricyclic 
antidepressants, some of the anthistamines that are 
on the market, or the Parkinson agents may have 
some anticholingeric properties. The reason that 
some practitioners may want to avoid the use of these 
medications in the geriatric population is because they 
are known to cause some confusion, constipation, dry 
mouth, some hypotension to occur in certain cases. So 
they usually try to avoid these medications if the risk 
outweighs the benefit in that particular population. 
This also goes for the use of benzodiazepines. Use is 
usually avoided because of their side effect profile as 
well. The potential to cause cognitive impairments or 
even worsening of cognitive impairment, confusion, 
risk of fall, risk of fracture, or just general impairment 
overall.  When it comes to that medication class, the 
side effect profile is looked at as well as the potential 
for hepatic metabolism. There are some drugs that 
undergo hepatic metabolism, and with the decline of 
hepatic functioning in the geriatric population, they try 
to avoid the use of the longer-acting benzodiazepine 
agents in that population if it is not really needed. 
Dr. Kundart: Okay, so we have the Parkinson drugs, 
anticholingerics causing what I believe sounds like 
a triage, confusion, constipation, and I might make a 
third suggestion to complete the alliteration—cotton 
mouth, or dry mouth. Benzodiazepines also cause 
confusion, risk of falls you say. It sounds like if the 
practitioner is prescribing these because they had good 
clinical experience, perhaps with a slightly younger 
patient population. Also, we have the pharmacist 
who knows contraindications for these meds.  It must 
create a difficult situation where there has to be some 
communication in the interprofessional manner 
between the two parties. Is that right?
Dr. Farinde: Correct, and in most cases, whether it 
is a pharmacist doing the initial assessment of the 
medication profile there is that communication that 
occurs between the prescribing provider and the 
clinical pharmacist. Whoever may have identified this 
potential interaction, we need to look at whether this is 
a risk to the patient by starting them on this medication 
or even continuing the medication if it has already been 
initiated—whether or not there is that benefit if an 
anticholingeric agent is initiated or a medication that 
has an anticholingeric property, or even the use of a 
benzodiazepine in certain cases. 
Dr. Kundart: How does it work best with physicians 
being the prescribing party in this country, and with 
the pharmacist seeing the larger drug interaction 
picture, how does it work that the two professions 
can work interprofessionally to avoid these types of 
contraindications?
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Dr. Farinde: I think one of the best ways or one of the 
best forms to occur is to have a therapeutic committee 
meeting or a forum where both professions are able to 
come together to sit down and discuss certain guidelines 
that should be in place for prescribing medications. 
In some hospital settings or other healthcare settings, 
it may be there is the presence of a formulary which 
helps to determine which medications should be used 
in certain disease states or conditions and they look at 
costs but they also look at patient outcomes, such as 
whether or not this medication might be better if it is 
used in this population, or if it is better to be used in a 
condition or disease state. So there is that side-by-side 
comparison that occurs if they are able to come together 
and actually sit down and talk about which medication 
is best for the patients that they are caring for.
Dr. Kundart: I know from our last interview you’ve had 
an opportunity to be on this kind of panel at an assisted 
living center. Is that correct?
Dr. Farinde: Correct, and this served as a platform 
where as a pharmacist if you are doing an evaluation 
of a medication profile, you might come across a 
glaring contraindication or something that really is 
not appropriate. For example in a geriatric patient, 
you would make this known to the prescriber at that 
particular meeting. They have ongoing assessment of 
the patients’ conditions as well, too, which also allows 
for different disciplines to come together and actually 
know what is going on, what they are doing as part of the 
care of the patient, and this allows for the prescribers, 
the nurses, the psychologist, whoever it may be to voice 
their concerns about the patient’s treatment.
Dr. Kundart: So I think the assisted living center 
situation is very interprofessional, where you have the 
pharmacists and also the physician in the same room 
at the same time and other allied health professionals. 
It may only happen when the patient can’t otherwise 
speak for themselves, and I think in your case, it was 
done for folks that had various mental health issues. Is 
that the right understanding? Patients that can speak for 
themselves because they’re young or don’t have mental 
health issues, for example, might not have this advantage 
of having this interprofessional collaboration.
Dr. Farinde: Correct. In the particular facility where I 
was, a large number of the individuals were nonverbal, 
and some of course were not ambulatory, so a majority 
of the treatment involved the collaboration of these 
different disciplines. It was our responsibility to make 
sure that not only were their medication therapies 
being met, or addressed appropriately, but also behavior 
related issues, psychological issues, medical conditions 
were also being handled appropriately during these 
team meetings because this is where everybody is able 
to come together. If one discipline does not notice an 
issue with something, another discipline might notice 
and bring it to the attention of others. So you get insight 
into patients’ conditions or conditions based on these 
needs that is very vital, a part of providing optimal 
patient care.
Dr. Kundart: It is of course true that these adverse 
interactions may not occur with the strong 
anticholingerics or Parkinson drug, or benzodiazepines 
but may also occur with drugs used to treat urinary tract 
infection or UTI. You were talking about something in 
your article about Macrobid (nitrofuratoin) and how it 
may have serious pulmonary and hepatic side effects on 
seniors. Can you tell us a little bit more about that case?
Dr. Farinde: Well I think with Macrobid, there is 
somewhat of a divide because right now it currently 
says that you shouldn’t use or use should be avoided 
in geriatric population. This is based on the fact that 
it can potentially cause pulmonary toxicity, whether 
it may be an acute form, subacute, or chronic and 
that can usually occur after 6 months of therapy if 
an individual has been on it. So there is that general 
avoidance of long-term use when it comes to the 
treatment of urinary tract infections. That is one of 
the reasons they want to avoid it.  The second may 
be the potential for the development of peripheral 
neuropathy: even though it may be rare, they try to 
avoid Macrobid because of this potential side effect. 
There are certain individuals with certain disease states 
that are more predisposed to developing the peripheral 
neuropathy or the pulmonary toxicity. Some of those 
patients have debilitating diseases like individuals that I 
encountered when I was at the supported living center. 
Individuals with renal impairment align with our 
geriatric population as well as individuals with anemia 
or diabetes. So all of these factors have to be considered 
even before you consider the use of Macrobid. When 
it comes to renal functioning, there is the rule that you 
should avoid if their clearance is less than 60, but on the 
spectrum there is limited data that suggests that if its 
greater than or equal to 40 you can use it for less than 
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a week (short-term period) for an uncomplicated UTI 
which you treat for 3-5 days. So there is that conflict 
when it comes to the use of Macrobid in that respect. 
So I have run across cases where it is based on clinical 
judgment. If  a  prescriber has used Macrobid in the 
past and it was thought to be successful in an older 
individual they are more likely to give the medication. 
On the other spectrum, if a prescriber is new and has 
never come across the use of Macrobid and they see 
that this person’s renal function is slowly declining they 
may want to avoid the use of this medication and try 
something else. 
Dr. Kundart: I must say that I am probably not the 
only person listening who is unaware, being that I am 
a pediatric practitioner that some of your seniors are 
getting their urinary tract infection treated over six 
months or a longer period of time. There is a whole 
other world for folks that are receiving this kind of 
ongoing care where interprofessional collaboration 
becomes all the more important. 
Dr. Farinde: Correct.  I think this provides a perfect 
platform for other recommendations for other agents 
to be used if there is that doubt as to whether this 
medication, given all the potential adverse effects that 
may develop and also increased potential if the person 
is a geriatric patient, you may want to consider using 
other alternative antibiotics to treat this UTI.
Dr. Kundart: I hope that as well. It is always difficult in 
pharmacy to move from tried-and-true, accepted drugs 
to ones that are newer, and perhaps more expensive, but 
not used as extensively by the practitioner as ones that 
they are used to,  despite perhaps a better side effect 
profile. Or maybe, on the other hand, we just learn 
about new side effects from new medications as time 
goes by. 
Dr. Farinde: Correct.  A large majority of what has 
come out about nitrofurantoin or Macrobid has been 
through postmarketing analysis because usually some 
of these do come out after the fact. We can’t get all of the 
information in terms of potential side effects during the 
clinical trial phase so after the fact we are able to have 
this additional information and make future treatment 
decisions or more informed treatment decisions based 
on this new information that has become available.  As a 
result of that, there are other treatment options that can 
be made available or prescribers can be informed about 
other treatment options that may not pose the same 
risk given the sensitivity of our geriatric population.
Dr. Kundart: It is very interesting topic. Is there anything 
else you would like to add concerning the use of these 
medications and working with this population?
Dr. Farinde: Well, I think that when it comes to the 
geriatric population, the key points are to assess renal 
function, hepatic function, immune system, and look at 
whether the patient is able to tolerate the medication. 
We have these guidelines in place to help guide us 
when it comes to whether medication are deemed to be 
appropriate or inappropriate for use in this population. 
I think it does serve a world of good for this population 
if we can avoid the adverse reactions that are becoming 
so prevalent sometimes when it comes to treating this 
population.
Dr. Kundart: Very good advice I think. I think unless 
you have more to add we will probably end it there.
Dr. Farinde: Thank you very much.
Abimbola Farinde is a clinical pharmacist specialist 
(psychopharmacology and geriatrics).
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